Reading Hospital
TOWER HEALTH
Advancing Health. Transforming Lives.

CLINICAL TRIALS OFFICE
research@towerhealth.org
DOB, Suite 355
484-628-8585

Full Title	A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome – the AEGIS-II Study
Principal Investigator	Earl Hope, MD
Sub-Investigators	Eric Elgin, MD
Study Objectives	To evaluate the efficacy of CSL112 on reducing the risk of MACE (CV death, MI, or stroke) from the time of randomization through 90 days in subjects with ACS (diagnosed with STEMI or NSTEMI)
Inclusion Criteria	• Male or female at least 18 years of age • Evidence of myocardial necrosis in a clinical setting consistent with type 1 MI • Evidence of multivessel coronary artery disease • Established protocol defined risk factors • Post-menopausal, negative pregnancy test and acceptable protocol defined methods of contraception
Exclusion Criteria	• Hemodynamic instability defined by protocol • Evidence of hepatobiliary disease • Evidence of severe chronic kidney disease • Plan to undergo scheduled coronary artery bypass graft surgery after randomization • Allergic to investigational product or soy beans or peanuts • Severe comorbid conditions defined by the protocol
Affiliations & Sponsors	CSL Behring
Status	Open to Enrollment
Keywords	ACS, NSTEMI, STEMI, Apolipoprotein A-I